Ischemia and No Obstructive Coronary Artery Disease: Prevalence and Correlates of Coronary Vasomotion Disorders.
Thomas J Ford, Eric Yii, Novalia Sidik...
https://pubmed.ncbi.nlm.nih.gov/31833416/Actively Recruiting
Led by NHS Greater Glasgow and Clyde · Updated on 2026-04-09
1500
Participants Needed
39
Research Sites
235 weeks
Total Duration
This research investigates whether personalized medical treatment guided by a special diagnostic procedure during invasive coronary angiography can improve symptoms, wellbeing, cardiovascular risk, and clinical outcomes in patients with angina but no significant blockage in their coronary arteries. It focuses on patients with ischaemic heart disease, particularly those with angina without obstructive coronary artery disease INOCA, a condition affecting the small vessels of the heart. The trial builds on earlier pilot studies that suggested this approach could improve quality of life and symptom control by tailoring diagnosis and treatment more precisely. Participants undergo functional coronary angiography with a guidewire-based interventional diagnostic procedure IDP that measures coronary vascular function to classify patients into specific diagnosis groups, such as microvascular or vasospastic angina. Eligible patients are randomized into two groups one where IDP results are disclosed to clinicians to guide treatment, and another where IDP is performed but results are hidden, with care based on standard angiography and clinical information. Both groups receive medical therapy and lifestyle advice based on their diagnosis. The study also includes a registry for patients with obstructive disease who are not randomized. During the study, participants complete symptom questionnaires like the Seattle Angina Questionnaire to assess their angina symptoms and quality of life over at least 12 months. Researchers monitor health status, clinical outcomes, safety, and health economics, with ongoing follow-up planned for up to 10 years. Both patients and their usual care clinicians are blinded to the group allocation, but informed about the diagnosis to guide treatment. The trial aims to enroll 1500 participants across multiple centers in Europe, assessing the feasibility and impact of this stratified medicine approach.
CONDITIONS
iCorMicA - Stratified Medicine in Angina
C
Colin Berry, MBChB, PhD
D
Daniel Ang, MBChB
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
NHS Greater Glasgow and Clyde
Lead Sponsor
University of Glasgow
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit (in-person)
Duration - Same day as enrollment
Participants undergo invasive coronary angiography with an interventional diagnostic procedure (IDP) using a guidewire to assess coronary vascular function and determine their specific angina type (endotype).
1 visit (in-person) for invasive coronary angiography and IDP
Duration - Up to 12 months
Participants receive medical therapy and lifestyle recommendations tailored to their specific angina endotype based on IDP results or standard care if IDP results are blinded.
Regular follow-up visits as per clinical care during the 12-month treatment period
Duration - Up to 10 years
Participants are followed for health outcomes, symptom assessment, and safety monitoring using patient-reported outcome measures and clinical assessments beyond the initial treatment period.
Periodic follow-up visits and electronic health record linkage
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Thomas J Ford, Eric Yii, Novalia Sidik...
https://pubmed.ncbi.nlm.nih.gov/31833416/Vijay Kunadian, Alaide Chieffo, Paolo G Camici...
https://pubmed.ncbi.nlm.nih.gov/32626906/Daniel T Y Ang, Damien G Collison, Ross J McGeoch...
https://pubmed.ncbi.nlm.nih.gov/40308206/Peter Ong, Paolo G Camici, John F Beltrame...
https://pubmed.ncbi.nlm.nih.gov/29031990/Jaskanwal D Sara, R Jay Widmer, Yasushi Matsuzawa...
https://pubmed.ncbi.nlm.nih.gov/26404197/Juhani Knuuti, William Wijns, Antti Saraste...
https://pubmed.ncbi.nlm.nih.gov/31504439/C Noel Bairey Merz, Carl J Pepine, Mary Norine Walsh...
https://pubmed.ncbi.nlm.nih.gov/28289007/Lasse Jespersen, Anders Hvelplund, Steen Z Abildstrøm...
https://pubmed.ncbi.nlm.nih.gov/21911339/Thomas J Ford, Bethany Stanley, Richard Good...
https://pubmed.ncbi.nlm.nih.gov/30266608/Thomas J Ford, Bethany Stanley, Novalia Sidik...
https://pubmed.ncbi.nlm.nih.gov/31709984/NHS Greater Glasgow and Clyde
Lead Sponsor
University of Glasgow
Collaborating Sponsor